143 results on '"Petri M"'
Search Results
2. POS0190 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES
3. POS0183 THE EFFECT OF BELIMUMAB ON SRI-4 RESPONSE IN MULTIPLE SUBGROUPS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS
4. POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS
5. OP0296 THE 2021 DORIS DEFINITION OF REMISSION IN SLE – FINAL RECOMMENDATIONS FROM AN INTERNATIONAL TASK FORCE
6. OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT
7. POS0304 EPIDEMIOLOGY AND ECONOMIC BURDEN ASSOCIATED WITH MENTAL HEALTH COMORBIDITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS PATIENTS
8. FRI0163 ANTIPHOSPHOLIPID PATTERNS PREDICT THE RISK OF THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
9. OP0160 HYDROXYCHLOROQUINE BLOOD LEVELS AND RISK OF THROMBOTIC EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
10. FRI0173 IDENTIFICATION OF RISK FACTORS FOR DEVELOPMENT OF OSTEONECROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
11. OP0045 DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL
12. SAT0203 SINGLE LAC POSITIVITY VERSUS DOUBLE AND TRIPLE POSITIVITY FOR THROMBOSIS IN SLE
13. SAT0167 RACIAL DIFFERENCES IN THE IMPACT OF HYDROXYCHLOROQUINE ON IMMUNOLOGIC MARKERS IN SLE PATIENTS
14. SAT0529 Hydroxychloroquine Retinopathy: Update on Application of The 2011 Screening Guidelines in An Academic Practice
15. OP0183 Hypocomplementemia Associates with Thrombosis in SLE Patients with Antiphospholipid Antibodies: Table 1.
16. THU0339 Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus
17. FRI0312 Predictors of Incident Episodes of Proteinuria among Patients with Systemic Lupus Erythematosus
18. FRI0353 A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using A Multistate Markov Model Approach: Table 1.
19. THU0304 Adherence To Hydroxychloroquine as Assessed by Measurements of Drug and Metabolite Blood Levels in An International Prospective Study of Sle Patients in Flare
20. THU0360 Application of New Definitions of Remission in SLE: Durable Remission Is Rare
21. AB0146 Self-Reactive IGE Exacerbates Interferon Responses Associated with Autoimmunity
22. SAT0325 Smoking Is Associated with Future Lupus Cutaneous Activity in Prospective Analyses
23. FRI0336 Hypocomplementemia in Systemic Lupus Erythematosus; Establishing The Importance of Low C3 and C4 in A Longitudinal Cohort: Table 1
24. AB0159 Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable To Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients
25. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort
26. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
27. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year
28. OP0185 Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity
29. SAT0428 Application of New Eular Definitions of Remission in SLE: Durable One-Year Remission is Rare: Table 1.
30. FRI0387 Association of Pre-Pregnancy Body Mass Index with Preterm Birth and Birthweight Percentiles in Systemic Lupus Erythematosus
31. SAT0385 Disease Activity Patterns Over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort
32. OP0079 Pharmacodynamic Changes in Gene Expression Observed in Two Phase 3 Trials of Baff Blockade with Tabalumab in SLE
33. THU0387 Effects of Blisibimod, An Inhibitor of B Cell Activating Factor, On Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus
34. FRI0381 Interferon Dysregulation in an Academic SLE Cohort is Associated with Distinct Signaling Differences in Blood Neutrophils VS. Peripheral Blood Mononuclear Cells
35. OP0187 Hydroxychloroquine Blood Levels in Sle: Clarifying Dosing Controversies and Improving Adherence
36. OP0092 Remission in Sle: Consensus Findings from a Large International Panel on Definitions of Remission in SLE (DORIS)
37. FRI0423 Impact of Disease Activity on Organ Damage Risk Over Time in Systemic Lupus Erythematosus – The Hopkins Lupus Cohort: Table 1.
38. FRI0406 Small LDL-P Increases with Increased Disease Activity in SLE
39. FRI0405 Prednisone Increases Both Arterial and Venous Thrombosis in SLE: Table 1.
40. OP0093 The Natural History of Thrombotic Events in Systemic Lupus Erythematosus and Associated Risk Factors: Table 1.
41. Response to: ‘Belimumab and the measurement of fatigue’ by Mazzoni
42. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus--the Hopkins Lupus Cohort
43. A6.44 Only BAFF mRNA, not BAFF protein level in blood, is associated with SLE activity over one year
44. THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus
45. AB0486 The Complete Response in Patients with Lupus Nephritis Treated with Mycophenolate Mofetil (MMF) as Their First Line Therapy: Table 1
46. OP0041 Pregnancy Outcomes for Systemic Lupus Erythematosus (SLE) Subjects with Conception during Belimumab Intravenous (IV) and Subcutaneous (SC) Placebo-Controlled Clinical Trials and Long Term Extension Trials
47. SAT0028 Pregnancy Outcomes in Systemic Lupus Erythematosus: Experiences from A Single US Academic Medical Center – Hopkins Lupus Pregnancy Cohort
48. FRI0388 Effects of Blisibimod on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies
49. FRI0431 Venous and Arterial Thrombosis in Sle: Differences in Natural History: Table 1.
50. FRI0389 Effects of Chronic Treatment with Subcutaneous Blisibimod on Renal and Inflammation Biomarkers in Subjects with Systemic Lupus Erythematosus in Phase 2 PEARL-SC and Open-Label Extension Studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.